{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:14:52Z","timestamp":1787494492503,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1016\/j.jaad.2006.07.027","type":"journal-article","created":{"date-parts":[[2007,1,23]],"date-time":"2007-01-23T07:58:09Z","timestamp":1169539089000},"page":"624-628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":108,"title":["Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients"],"prefix":"10.1016","volume":"56","author":[{"given":"Laurence","family":"Fardet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Dupuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Kerob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Allez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Begon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Bachelez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Morel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2006.07.027_bib1","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0190-9622(96)90321-7","article-title":"The prevalence of hidradenitis suppurativa and its potential precursor lesions","volume":"35","author":"Jemec","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.1985.tb02037.x","article-title":"Evidence of\u00a0genetic factors in hidradenitis suppurativa","volume":"113","author":"Fitzsimmons","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib4","first-page":"971","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J\u00a0Am\u00a0Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib5","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2133.1986.tb05740.x","article-title":"A double-blind controlled cross-over trial of cyproterone acetate in females with hidradenitis suppurativa","volume":"115","author":"Mortimer","year":"1986","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1136\/bmj.294.6570.487","article-title":"Recurrence after surgical treatment of hidradenitis suppurativa","volume":"294","author":"Harrison","year":"1987","journal-title":"Br Med J"},{"key":"10.1016\/j.jaad.2006.07.027_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/09546630410024547","article-title":"Treatment of hidradenitis suppurativa with infliximab in a patient with Crohn's disease","volume":"16","author":"Rosi","year":"2005","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.jaad.2006.07.027_bib8","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s00535-003-1185-9","article-title":"Hidradenitis suppurativa associated with Crohn's disease and spondyloarthropathy: response to anti-TNF therapy","volume":"38","author":"Roussomoustakaki","year":"2003","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jaad.2006.07.027_bib9","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.1572-0241.2002.05950.x","article-title":"Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn's disease patient","volume":"97","author":"Katsanos","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2006.07.027_bib10","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S0190-9622(03)01132-0","article-title":"Infliximab for the treatment of hidradenitis suppurativa","volume":"49","author":"Lebwohl","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00054725-200111000-00008","article-title":"Hidradenitis suppurativa and Crohn's disease: response to treatment with infliximab","volume":"7","author":"Martinez","year":"2001","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2006.07.027_bib12","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1365-2133.2003.05663.x","article-title":"Infliximab for hidradenitis suppurativa","volume":"149","author":"Sullivan","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1001\/archderm.139.12.1540","article-title":"Severe hidradenitis suppurativa treated with infliximab infusion","volume":"139","author":"Adams","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1046\/j.1365-2133.2003.05390.x","article-title":"Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa","volume":"149","author":"Sartorius","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib15","first-page":"177","article-title":"The French version of Skindex (Skindex-France): adaptation and assessment of psychometric properties","volume":"130","author":"Leplege","year":"2003","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2006.07.027_bib16","unstructured":"National Cancer Institute. Common terminology criteria for adverse events v3.0. Available from: http:\/\/ctep.cancer.gov. Accessed September 15, 2006."},{"key":"10.1016\/j.jaad.2006.07.027_bib17","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1365-2133.1996.d01-1069.x","article-title":"Hidradenitis suppurativa or acne inversa: a clinicopathological study of early lesions","volume":"135","author":"Boer","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib18","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/j.1365-2133.1990.tb06264.x","article-title":"Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands","volume":"122","author":"Yu","year":"1990","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0007-1226(03)00177-2","article-title":"Hidradenitis suppurativa: pathogenesis and management","volume":"56","author":"Slade","year":"2003","journal-title":"Br J Plast Surg"},{"key":"10.1016\/j.jaad.2006.07.027_bib20","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.1995.tb02624.x","article-title":"The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands","volume":"133","author":"Attanoos","year":"1995","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: effective in the management of hidradenitis suppurativa","volume":"154","author":"Cusack","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2006.07.027_bib22","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease: Crohn's disease cA2 study group","volume":"337","author":"Targan","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2006.07.027_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0016-5085(99)70005-3","article-title":"Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial","volume":"116","author":"D'haens","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2006.07.027_bib24","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for\u00a0plaque-type psoriasis: a randomized trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.07.027_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1365-2559.1993.tb00468.x","article-title":"Granulomatous hidradenitis suppurativa and cutaneous Crohn's disease","volume":"23","author":"Attanoos","year":"1993","journal-title":"Histopathology"},{"key":"10.1016\/j.jaad.2006.07.027_bib26","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0140-6736(05)67566-6","article-title":"Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial","volume":"366","author":"Reich","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2006.07.027_bib27","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for\u00a0dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2006.07.027_bib28","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1136\/ard.2005.037499","article-title":"Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis","volume":"64","author":"Sany","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2006.07.027_bib29","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","article-title":"Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium","volume":"11","author":"Jacobstein","year":"2005","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2006.07.027_bib30","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaad.2006.07.027_bib31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1085-9489.2005.00053.x","article-title":"Multifocal motor neuropathy during treatment with infliximab","volume":"10","author":"Cocito","year":"2005","journal-title":"J Peripher Nerv Syst"},{"key":"10.1016\/j.jaad.2006.07.027_bib32","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/rheumatology\/keh439","article-title":"Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy","volume":"44","author":"Rodriguez-Escalera","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2006.07.027_bib33","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1212\/01.WNL.0000142974.81103.95","article-title":"Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy","volume":"63","author":"Singer","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2006.07.027_bib34","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.326.7389.579","article-title":"Bilateral anterior toxic optic neuropathy and the use of infliximab","volume":"326","author":"ten Tusscher","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jaad.2006.07.027_bib35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0181-5512(05)81044-7","article-title":"Optic neuritis associated with infliximab","volume":"28","author":"Tran","year":"2005","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jaad.2006.07.027_bib36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archopht.122.5.793","article-title":"Infliximab-associated retrobulbar optic neuritis","volume":"122","author":"Mejico","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jaad.2006.07.027_bib37","doi-asserted-by":"crossref","first-page":"W34","DOI":"10.7326\/0003-4819-140-8-200404200-00037-w4","article-title":"Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease","volume":"140","author":"Strong","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2006.07.027_bib38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1212\/01.WNL.0000158681.29117.8B","article-title":"Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers","volume":"64","author":"Richez","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jaad.2006.07.027_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.mcg.0000155126.82171.32","article-title":"Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis","volume":"39","author":"Enayati","year":"2005","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jaad.2006.07.027_bib40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/00054725-200401000-00004","article-title":"Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease","volume":"10","author":"Thomas","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaad.2006.07.027_bib41","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206022699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962206022699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:06:28Z","timestamp":1759269988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962206022699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0190962206022699"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2006.07.027","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infliximab for severe hidradenitis suppurativa: Transient clinical efficacy in 7 consecutive patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2006.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}